GUIDELINES FOR USE OF ALBUMIN
Adapted from the original published guidelines developed by the University Hospital Consortium and published in
Archives of Internal Medicine, Vol 155, Feb 27, 1995
[Revised – 2005 & 2010]

Background

- The Consortium guidelines from 1995 addressed 12 indications and often did not recommend the FDA-approved
  indications as first line therapy. They were presented in an effort to minimize unnecessary use of albumin
  during an extended shortage that even today requires monthly allocations.
- Many trials have been published since 1995 and revision of UHS guidelines is long overdue.
- A Drug Usage Evaluation (DUE) performed in May 2009 revealed only 53% of albumin use met the current usage
  criteria. It also showed that 70% of the albumin use was from three services: Medicine, Transplant &
  Cardiothoracic Surgery.
- Non-protein colloids (hetastarch and dextrans) were offered as first-line, less costly alternatives in the 1995
  guidelines & for several indications stated that albumin should be reserved for cases where non-protein colloids
  were contraindicated. However, non-protein colloids have subsequently been implicated in bleeding
  abnormalities & high-molecular-weight dextrans are no longer available. In addition, the DUE clearly showed
  that clinicians were not considering non-protein colloids as viable first-line alternatives – even for FDA-approved
  indications. One of the recommendations of the DUE was to remove from the UHS Guidelines any statements
  that require non-protein colloids be contraindicated before albumin can be used. [This was done at P&T meeting
  in February]
- Albumin is available in 5% and 25% strengths. 25 g is osmotically equivalent to about 500 mL of fresh frozen
  plasma. In general, 5% is intended to restore plasma volume while the 25% will raise oncotic pressure
  (Micromedex® 2010)
- The debate over effectiveness of crystalloids vs. non-protein colloids vs. albumin continues. A Cochrane review
  from 2009 --“Colloids vs Crystalloids for fluid resuscitation in critically ill patients (Review)"-- by Perel et.al.
  concludes: “There is no evidence from [randomized-controlled trials] that resuscitation with colloids reduces the
  risk of death, compared to resuscitation with crystalloids, in patients with trauma, burns or following surgery….Clinical
  studies have shown that colloids & crystalloids have different effects on a range of important
  physiologic parameters. Because of these differences, all cause mortality is arguably the most clinically
  relevant outcome measure…. The choice of fluid has considerable cost implications. Volume replacement with
  colloids is considerably more expensive than with crystalloids.”
- See last page for UHS cost comparisons which underline the need for judicious use of albumin

<table>
<thead>
<tr>
<th>Indication</th>
<th>Guideline</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hemorrhagic shock</td>
<td>Crystalloids should be considered the initial resuscitation fluid of choice; colloids are appropriate for resuscitation in conjunction with crystalloids when blood products are not immediately available; Once the diagnosis of severe hypovolemia with or without shock is established, treatment is centered on rapid correction of the intravascular fluid deficit via crystalloid infusion; red blood cells should be used if there is ongoing hemorrhage or severe anemia. There are no strong data to support the routine use of colloid-based solutions, including albumin, in the management of severe hypovolemia. (UpToDate® 2010)</td>
</tr>
<tr>
<td>Nonhemorrhagic shock</td>
<td>Crystalloids should be considered first-line therapy; Clinical trials have failed to consistently demonstrate a difference between colloid &amp; crystalloid in the treatment of septic shock….giving a sufficient quantity of IV fluids rapidly &amp; targeting appropriate goals are more important than the type of fluid  (Schmidt, et al UpToDate® 2010)</td>
</tr>
<tr>
<td>Hepatic resection</td>
<td>Crystalloid use is recommended to maintain effective circulating volume following major (&gt;40%) hepatic resection; the use of hetastarch/dextran and albumin is also appropriate, depending on the function of the residual liver and hemodynamic status</td>
</tr>
<tr>
<td>Thermal injury</td>
<td>Crystalloid solutions should be used for initial fluid resuscitation (within the first 24 hours); colloids should be administered in conjunction with crystalloids if all of the following are true: 1. Burns cover &gt; 50% of the patients body surface; 2. At least 24 hours have passed since the burn occurred; 3. Crystalloid therapy has failed to correct hypovolemia. An FDA-approved indication in adults</td>
</tr>
<tr>
<td>Indication</td>
<td>Guideline</td>
</tr>
<tr>
<td>------------</td>
<td>-----------</td>
</tr>
</tbody>
</table>
| Cerebral ischemia or hemorrhage | • In the Neurosurgical ICU patient, crystalloids & colloids (primarily NS & albumin) may be used to maintain normovolemia or even hypervolemia as part of “triple H” therapy (hypertension, hypervolemia, hemodilution) as follows:  
  o For aneurysmal subarachnoid hemorrhage  
    - total fluids should be adjusted to maintain target CVP of 6 to 8 to decrease risk of vasospasm  
    - If delayed vasospasm occurs, hypervolemia should be induced to maintain CVP goal of 8 to 12  
  o For acute ischemic stroke or TIA if there is evidence of flow failure  
  o Dose: 5% albumin, 250 mL bolus every 2 – 4 hours PRN CVP goal; adjust rate of crystalloids by 25% if patient requires frequent albumin doses  
  • Patients with elevated hematocrit levels on admission should receive crystalloid solutions to increase intravascular volume, creating a state of hypervolemia and hemodilution (hematocrit levels of approximately 30% to maximize cerebral perfusion). |
| Nutritional intervention | • Albumin should not be used as a supplemental source of protein calories in patients requiring nutritional intervention.  
  • However, patients with diarrhea associated with enteral feeding intolerance may benefit from the administration of albumin if all the following conditions are met:  
    1. Significant diarrhea (> 2 liters per day) occurs;  
    2. Serum albumin is < 2.0 g/dl;  
    3. Continued diarrhea occurs despite trial of short-chain peptide and elemental formulas;  
    4. Other causes of diarrhea have been considered and ruled out. |
| Cardiac surgery UHS Guidelines Updated in 2005 | Guidelines for Albumin Use for Volume Expansion by Cardiothoracic Surgery; submitted by A. J. Carpenter, MD, PhD, Director, Cardiothoracic Surgery; Approved by P&T Committee in March 2005  
  • Patients undergoing cardiopulmonary bypass have marked dilution of intravascular colloid oncotic pressure  
  • During the early postoperative period, these patients typically require significant volume replacement due to peripheral vasodilation  
  • The best volume expander in this setting is albumin, and it is essential that the albumin be immediately available when needed  
  • Guidelines for the use of albumin in the post-cardiopulmonary bypass patient are as follows:  
    1. Replace volume as clinically indicated with 5% albumin given through a fluid warmer during the early post-operative period (up to 3 hours)  
    2. If large volumes are required, change to normal saline after 1500 mL of albumin have been given  
  • It is essential that albumin be in the PYXIS with “over-ride” authorization in order to have the fluid immediately available |
| Hyperbilirubinemia of the newborn | • An FDA-approved indication for 25% albumin  
  • According to Micromedex, evidence is inconclusive  
  • Should not be administered in conjunction with phototherapy, nor should it be used prior to exchange transfusion.  
  • It has been used with mixed results as an adjuvant to exchange transfusions and should be administered only with concurrent transfusion of blood.  
  • Crystalloids & non-protein colloids do not have bilirubin-binding properties and should not be considered as alternatives to albumin. |
| Acute Nephropathy, Nephrosis, Nephrotic syndrome & subsequent hypoalbuminemia | • Short-term albumin use, in conjunction with diuretic therapy, is appropriate for patients with acute, severe peripheral or pulmonary edema who have failed diuretic therapy  
  • Although an FDA-approved indication for 25% albumin for acute situations, it is ineffective in chronic conditions (Micromedex® 2010)  
  • Review of clinical studies suggests lack of benefit if hypoalbuminemia is caused by inadequate production, excessive catabolism or proteinuria (Micromedex® 2010)  
  • While giving 25% albumin to raise oncotic pressure can result in an increase of sodium excretion & lead to resolution of edema, this response is not seen in all patients or even in the same patient on different occasions. (UpToDate™ 2010) |
<table>
<thead>
<tr>
<th>Indication</th>
<th>Guideline</th>
</tr>
</thead>
</table>
| **Ascites, Cirrhosis, Paracentesis, Spontaneous Bacterial peritonitis & Hepatorenal Syndrome** | - Ascites removal of < 4 liters: **Crystalloids should be considered the solution of choice** to prevent complications such as reduced effective plasma volume, renal dysfunction, etc.  
- Ascites removal of > 4 liters: **Consider Albumin for the prevention of complications. May use 6 to 8 g of albumin for each liter of ascitic fluid removed** (UpToDate® 2010)  
- Management of spontaneous bacterial peritonitis (SBP) & prevention of hepatorenal syndrome (HRS):  
  - in patients with cirrhosis and SBP, treatment with intravenous albumin in addition to an antibiotic reduces the incidence of renal impairment and death in comparison with treatment with an antibiotic alone. *(N Engl J Med 1999; 341:403-9.)*; patients with:  
    - ascitic fluid PMN counts ≥250 cells/mm3 (0.25 X 109/L)  
    - clinical suspicion of SBP,  
    - a serum creatinine >1 mg/dL  
    - blood urea nitrogen >30 mg/dL, or  
    - total bilirubin >4 mg/dL should receive **1.5 g albumin/kg body weight within 6 hours of detection and 1.0 g/kg on day three.** (UpToDate® 2010 & Gut 2007; 56:1310-1318)  
- Diagnosis of HRS:  
  - one of the criteria in making a diagnosis of HRS includes lack of improvement in renal function after discontinuation of diuretics and initiation of volume expansion with an **albumin infusion of 1 g/kg (up to 100 g) daily for 2 consecutive days.** (UpToDate® 2010)  
- Treatment of Type I HRS:  
  - **Albumin infusion plus administration of vasoactive drugs such as octreotide and midodrine should be considered** (UpToDate® 2010). Dose recommended by International Ascites Club (Gut 2007; 56:1310-1318) is **1 g/kg (max of 100 g)** followed by **20 to 40 g/day. (available as 25 g/100 mL bottles).**  
  - In addition to references mentioned above, see also American Academy for the Study of Liver Diseases (AASLD) Practice Guidelines: Management of Adult Patients with Ascites Due to Cirrhosis: An Update; Runyon, Hepatology 2009;Vol 49, No 6:2087-2107. These guidelines offer a Class and Level of Evidence with each recommendation and are posted on the UHS Clinical Intranet under “Albumin Use”. |
| **Organ transplantation** | - Albumin &/or non-protein colloid administration have not been demonstrated conclusively effective during &/or after renal transplantation surgery.  
- Albumin may be useful for postoperative liver transplant patients in the control of ascites and peripheral edema if all of the conditions are met:  
  1. Serum albumin is < 2.5 g/dl;  
  2. Pulmonary capillary wedge pressure is < 12 mm Hg;  
  3. Hematocrit is > 30%  
  In these cases, albumin may also be used to replace ascitic fluid lost through drainage catheters following liver transplantation. |
| **Plasmapheresis** | - Albumin, in conjunction with large-volume plasma exchange, is appropriate. Large-volume plasma exchange is defined as > 20 mL/kg in one session, or more than 20 mL/kg in repeated sessions.  
- Crystalloid solutions and albumin/crystalloid combination should be considered as cost-effective alternatives for smaller volume exchanges. |
| **Acute Respiratory Distress Syndrome (ARDS)** | - Fluid restriction is appropriate for patients with hemodynamically stable Acute Lung Injury (ALI)/ARDS; the combination of colloids (25% albumin) and diuretics may be considered in patients with hypo-oncotic ALI/ARDS. *(American Thoracic Society Consensus Statement 2004 and UpToDate® 2010)*  
- An FDA-approved indication for 25% albumin in adults  
- **Neuro-ICU dose recommendation:** Albumin 25% IV bolus every 6 to 12 hours PRN for 24 to 72 hours in combination with furosemide +/- chlorothiazide |
Indications with limited or inconclusive evidence in which colloid use is considered appropriate:

- Granulocytapheresis -- nonprotein colloid solution is appropriate as a sedimenting agent for donation of granulocytes and for acute cytoreduction in chronic myelogenous leukemia (chronic granulocytic leukemia).
- Stem cell cryopreservation -- nonprotein colloid solution is appropriate as part of a cryopreservation solution for frozen storage of hematopoietic stem cells.
- Pretreatment of Dacron aortic grafts -- albumin is appropriate to make grafts impervious to blood before insertion
- Red blood separation for major blood type incompatible bone marrow transplantation -- nonprotein colloids are appropriate

Indications with limited or inconclusive evidence in which albumin use is considered inappropriate:

- Severe hypoalbuminemia (without addressing primary causes)
- Increasing drug efficacy
- Uncomplicated pancreatitis.
- Traumatic brain injury (TBI) -- The Saline versus Albumin Fluid Evaluation (SAFE) study suggested that patients with TBI resuscitated with albumin had a higher mortality rate than those resuscitated with saline.
- Septic Shock -- clinical trials have failed to consistently demonstrate a difference between colloid and crystalloid in the treatment of septic shock

**FDA-Approved Indications & Contraindications for Non-Protein Colloids**

<table>
<thead>
<tr>
<th>FDA-approved Indications for low-molecular weight dextrans</th>
<th>Contraindications for low-molecular weight dextrans</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Adjunctive therapy of shock or impending shock due to hemorrhage, burns, surgery or other trauma</td>
<td></td>
</tr>
<tr>
<td>• Priming fluid in pump oxygenators during extracorporeal circulation</td>
<td></td>
</tr>
<tr>
<td>• Prophylaxis of VTE &amp; PE in patients undergoing procedures known to be associated with a high incidence of thromboembolic complications</td>
<td></td>
</tr>
<tr>
<td>• Known hypersensitivity</td>
<td></td>
</tr>
<tr>
<td>• Marked hemostatic defects including drug-induced defects by heparin or warfarin</td>
<td></td>
</tr>
<tr>
<td>• Marked cardiac decompensation</td>
<td></td>
</tr>
<tr>
<td>• Renal disease with severe oliguria or anuria</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>FDA-approved Indications for hetastarch</th>
<th>Contraindications for hetastarch</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Hypovolemia</td>
<td></td>
</tr>
<tr>
<td>• Adjunctive therapy in leukapheresis</td>
<td></td>
</tr>
<tr>
<td>• Known hypersensitivity</td>
<td></td>
</tr>
<tr>
<td>• Clinical conditions where volume overload is a potential problem (CHF, renal disease with oliguria or anuria not related to hypovolemia</td>
<td></td>
</tr>
<tr>
<td>• Pre-existing coagulation or bleeding disorders</td>
<td></td>
</tr>
</tbody>
</table>

Contributors: Michael Johnson MD, Augusto Parra MD, Rosa Garcia RPh, Colleen Barthol PharmD
Editors: Yolanda Laurel RPh,MS, Pharmacy Services, Alexander Shepherd MD, PhD, Chairman, Pharmacy & Therapeutics Committee
## Current UHS acquisition costs (February 2010) of common crystalloids and colloids

### CRYSTALLOIDS

<table>
<thead>
<tr>
<th>Crystalloid</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Normal Saline 1000 mL</td>
<td>$1.30</td>
</tr>
<tr>
<td>Lactated Ringer’s 1000 mL</td>
<td>$1.30</td>
</tr>
</tbody>
</table>

### NON-PROTEIN COLLOIDS

<table>
<thead>
<tr>
<th>Colloid</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dextran 40 (Low Molecular Weight) 10% in NS 500 mL</td>
<td>$20.75</td>
</tr>
<tr>
<td>Dextran 40 (Low Molecular Weight) 10% in D5 500 mL</td>
<td>$20.10</td>
</tr>
<tr>
<td>Hetastarch 6% in NS 500 mL</td>
<td>$18.75</td>
</tr>
</tbody>
</table>

### PROTEIN COLLOIDS

<table>
<thead>
<tr>
<th>Albumin %</th>
<th>Contract price</th>
<th>Off-contract Approximate Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>5% 50 mL</td>
<td>$23.66</td>
<td>NA</td>
</tr>
<tr>
<td>5% 250 mL</td>
<td>$34.32</td>
<td>$50.00</td>
</tr>
<tr>
<td>5% 500 mL</td>
<td>$68.64</td>
<td>$71.00</td>
</tr>
<tr>
<td>25% 20 mL</td>
<td>$22.08</td>
<td>NA</td>
</tr>
<tr>
<td>25% 50 mL</td>
<td>$34.32</td>
<td>$37.00</td>
</tr>
<tr>
<td>25% 100 mL</td>
<td>$68.64</td>
<td>$80.00</td>
</tr>
</tbody>
</table>